IONIS PHARMACEUTICALS INC (IONS) Forecast, Price Target & Analyst Ratings
NASDAQ:IONS • US4622221004
74.04 USD
-1.12 (-1.49%)
At close: Mar 6, 2026
73.625 USD
-0.42 (-0.56%)
After Hours: 3/6/2026, 8:27:08 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for IONIS PHARMACEUTICALS INC (IONS).
Forecast Snapshot
Consensus Price Target
$92.16
+ 24.48% Upside
Next Earnings Forecast
Release DateApr 28, 2026
PeriodQ1 / 2026
EPS Estimate-$0.90
Revenue Estimate199.47M
ChartMill Buy Consensus
81.38%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$92.16
Upside
+ 24.48%
From current price of $74.04 to mean target of $92.16, Based on 29 analyst forecasts
Low
$46.46
Median
$96.90
High
$115.50
Price Target Revisions
1 Month
2.65%
3 Months
8.11%
Price Target Summary
29 analysts have analysed IONS and the average price target is 92.16 USD. This implies a price increase of 24.48% is expected in the next year compared to the current price of 74.04.
The average price target has been revised upward by 8.11% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
81.38%
IONS was analyzed by 29 analysts. The buy percentage consensus is at 81. So analysts seem to be very confident about IONS.
In the previous month the buy percentage consensus was at a similar level.
IONS was analyzed by 29 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-03 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2026-02-27 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2026-02-26 | Needham | Maintains | Buy -> Buy |
| 2026-02-26 | Stifel | Maintains | Hold -> Hold |
| 2026-02-06 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2026-01-05 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-12-17 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-12-15 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-12-09 | B of A Securities | Maintains | Buy -> Buy |
| 2025-11-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-04 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-10-30 | TD Cowen | Maintains | Buy -> Buy |
| 2025-10-30 | Needham | Maintains | Buy -> Buy |
| 2025-10-30 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-10-30 | Barclays | Maintains | Overweight -> Overweight |
| 2025-10-30 | Raymond James | Reiterate | Strong Buy -> Strong Buy |
| 2025-10-30 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-10-30 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-16 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-10-08 | Needham | Maintains | Buy -> Buy |
| 2025-10-08 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-10-08 | JP Morgan | Upgrade | Neutral -> Overweight |
| 2025-10-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-10-06 | Stifel | Maintains | Hold -> Hold |
| 2025-09-26 | Goldman Sachs | Upgrade | Sell -> Neutral |
Next Earnings Forecast Details
Next Earnings Details
Release DateApr 28, 2026
PeriodQ1 / 2026
EPS Estimate-$0.90
Revenue Estimate199.47M
Revenue Q2Q51.11%
EPS Q2Q3.12%
Number of Analysts17
Next Earnings Revisions
Revenue (1 Month)
1.63%
Revenue (3 Months)
4.02%
EPS (1 Month)
-0.82%
EPS (3 Months)
-1.44%
Next Earnings Summary
IONS is expected to report earnings on 4/28/2026. The consensus EPS estimate for the next earnings is -0.9 USD and the consensus revenue estimate is 199.47M USD.
The next earnings revenue estimate has been revised upward by 4.02% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 787.647M 34.09% | 705.138M -10.48% | 943.711M 33.83% | 852.6M -9.65% | 1.419B 66.43% | 1.892B 33.33% | 2.745B 45.08% | 3.564B 29.84% | 4.3B 20.65% | 4.933B 14.72% | 5.292B 7.28% | |
| EBITDA YoY % growth | -320.879M 18.46% | -463.131M -44.33% | -369.237M 20.27% | -547.674M -48.33% | -134.015M 75.53% | -411.098M -206.76% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -333.73M 18.64% | -475.081M -42.35% | -381.684M 19.66% | -519.91M -36.21% | -246.481M 52.59% | 145.89M 159.19% | 748.65M 413.16% | 1.396B 86.47% | 1.892B 35.53% | 2.363B 24.89% | 2.621B 10.92% | |
| Operating Margin | -42.37% | -67.37% | -40.45% | -60.98% | -17.37% | 7.71% | 27.27% | 39.17% | 44.00% | 47.90% | 49.53% | |
| EPS YoY % growth | -2.56 11.42% | -3.04 -18.75% | -2.44 19.74% | -3.88 -58.89% | -1.50 61.35% | 0.50 133.13% | 4.04 713.28% | 6.47 60.37% | 8.56 32.18% | 9.99 16.72% | 10.93 9.39% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.90 3.12% | -1.02 -245.96% | -0.69 14.06% | -0.65 53.70% | -0.98 -8.68% | -0.83 19.14% | -0.60 12.46% | -0.44 32.81% |
| Revenue Q2Q % growth | 199.47M 51.11% | 194.2M -57.04% | 232.52M 48.10% | 242.97M 19.69% | 210.89M 5.73% | 242.96M 25.11% | 285.74M 22.89% | 318.28M 31.00% |
| EBITDA Q2Q % growth | -138.113M 4.12% | -175.732M -220.79% | -131.931M 12.99% | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -151.15M -2.92% | -171.414M -222.60% | -123.384M 22.97% | -121.019M 43.57% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
14.92%
EPS Next 5 Year
27.59%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
29.93%
Revenue Next 5 Year
32.80%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
21.55%
EBIT Next 5 Year
N/A
IONIS PHARMACEUTICALS INC / IONS Forecast FAQ
What is the price target for IONS stock?
29 analysts have analysed IONS and the average price target is 92.16 USD. This implies a price increase of 24.48% is expected in the next year compared to the current price of 74.04.
When does IONIS PHARMACEUTICALS INC (IONS) report earnings?
IONIS PHARMACEUTICALS INC (IONS) will report earnings on 2026-04-28.
What are the consensus estimates for IONS stock next earnings?
The consensus EPS estimate for the next earnings of IONIS PHARMACEUTICALS INC (IONS) is -0.9 USD and the consensus revenue estimate is 199.47M USD.
Can you provide the consensus rating for IONIS PHARMACEUTICALS INC stock?
The consensus rating for IONIS PHARMACEUTICALS INC (IONS) is 81.3793 / 100 . This indicates that analysts generally have a positive outlook on the stock.